Received Oct 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLU3 | INFLUENZA (SEASONAL) (FLULAVAL) | GLAXOSMITHKLINE BIOLOGICALS | 2 | F4A7R | — |
early 2nd dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too short in a 5-year-old female patient who received Flu Seasonal TIV Quebec (FluLaval 2025-2026 season) (batch number F4A7R, expiry date 06-JUN-2026) for prophylaxis. Concomitant products included Influenza vaccine inact split 3v (Flulaval). On 29-SEP-2025, the patient received the 2nd dose of FluLaval 2025-2026 season. On 29-SEP-2025, an unknown time after receiving FluLaval 2025-2026 season, the patient experienced drug dose administration interval too short (Verbatim: early 2nd dose). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 30-SEP-2025 A medical assistant had reported that someone else had given a child an early second dose of FluLaval. The child had never been vaccinated before and was scheduled to receive two doses. The first dose had been administered on 23rd September 2025, and the second dose had been given on 29 September 2025.; Sender's Comments: GSK-US2025125443:Same reporter/Diffrent patient